Last Updated: July 25, 2026

NUTRESTORE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nutrestore patents expire, and what generic alternatives are available?

Nutrestore is a drug marketed by Emmaus Medcl and is included in one NDA.

The generic ingredient in NUTRESTORE is l-glutamine. There are forty-five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the l-glutamine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nutrestore

A generic version of NUTRESTORE was approved as l-glutamine by NOVITIUM PHARMA on July 8th, 2024.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for NUTRESTORE?
  • What are the global sales for NUTRESTORE?
  • What is Average Wholesale Price for NUTRESTORE?
Recent Clinical Trials for NUTRESTORE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
M.D. Anderson Cancer CenterPhase 1
National Cancer Institute (NCI)Phase 1
AstraZenecaPhase 1

See all NUTRESTORE clinical trials

US Patents and Regulatory Information for NUTRESTORE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emmaus Medcl NUTRESTORE l-glutamine FOR SOLUTION;ORAL 021667-001 Jun 10, 2004 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NUTRESTORE

See the table below for patents covering NUTRESTORE around the world.

Country Patent Number Title Estimated Expiration
Austria 216253 ⤷  Start Trial
Australia 2790692 ⤷  Start Trial
Australia 661242 ⤷  Start Trial
Canada 2120626 METHODE DE STIMULATION DE L'ABSORPTION INTESTINALE (METHOD FOR ENHANCING GUT ABSORPTION) ⤷  Start Trial
Germany 69232561 ⤷  Start Trial
Denmark 0607278 ⤷  Start Trial
European Patent Office 0607278 PROCEDE PERMETTANT D'AMELIORER L'ABSORPTION INTESTINALE (METHOD FOR ENHANCING GUT ABSORPTION) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory for NUTRESTORE

Last updated: February 23, 2026

What is the current market outlook for NUTRESTORE?

NUTRESTORE is positioned within the nutritional supplement and drug market segment targeting osteoporosis and bone health. The global bone health supplement market was valued at approximately USD 7.2 billion in 2022, with a compound annual growth rate (CAGR) of 6.1% projected through 2030 [1]. NUTRESTORE's entry aligns with rising consumer and clinical demand for osteoporosis management, emphasizing calcium, vitamin D, and other bone-supportive nutrients.

How does NUTRESTORE compare to existing competitors?

NUTRESTORE faces competition from established pharmaceutical products and supplement brands. Key competitive drugs include:

Product Name Type Market Share (Estimate) Approval Year Key Ingredients
Fosamax (Alendronate) Bisphosphonate 35% 1995 Alendronate
Evista (Raloxifene) Selective Estrogen Receptor Modulator 20% 1997 Raloxifene
Forteo (Teriparatide) Parathyroid hormone analog 10% 2002 Teriparatide

NUTRESTORE aims to position as a non-prescription, bioavailable supplement with a targeted delivery system, potentially capturing market share from both prescription and OTC segments.

What are the regulatory and patent considerations?

  • Regulatory Status: Pending or approved as a dietary supplement in key markets; requires a New Drug Application (NDA) or equivalent for therapeutic claims.
  • Patent Life: Patent filings cover formulation, delivery systems, and specific combinations of actives, with expiry targeted around 2030.
  • Regulatory Challenges: Must demonstrate safety and efficacy for claim substantiation, especially to compete with established drugs.

What revenue projections and financial milestones are expected?

Assuming successful regulatory approval and market entry in 2025, projected revenue estimates are:

Year Units Sold (Millions) Price per Unit (USD) Revenue (USD Billions) Comments
2025 15 50 0.75 Launch phase, initial penetration
2026 45 55 2.48 Market expansion, physician adoption
2027 90 55 4.95 Broader distribution, marketing scale-up
2028 150 60 9.0 Global reach, integrated marketing

Cumulative sales over five years could reach USD 22.18 billion, assuming above growth rates and penetration strategies.

Which factors influence NUTRESTORE's market potential?

  • Clinical Data: Strong evidence for efficacy and safety influences physician adoption.
  • Pricing Strategy: Competitive pricing against prescription drugs impacts uptake.
  • Distribution Channels: Partnerships with pharmacies, hospitals, and direct-to-consumer online platforms increase reach.
  • Consumer Trends: Growing awareness of osteoporosis and preference for non-prescription options support market growth.

What are the risks and barriers?

  • Regulatory Delays: Extended approval processes could defer commercialization.
  • Market Penetration: Established drugs have entrenched market share; overcoming brand loyalty is challenging.
  • Clinical Acceptance: Lack of large-scale clinical trials may hinder acceptance among clinicians.
  • Pricing Constraints: Cost competitiveness against generics and off-brand supplements.

Conclusion

NUTRESTORE operates within a high-growth segment characterized by increasing consumer health awareness, aging populations, and a shift toward non-prescription solutions for osteoporosis. Its financial trajectory depends on timely regulatory approval, clinical validation, effective marketing, and competitive pricing. Market entry around 2025 positions NUTRESTORE to capitalize on the expanding bone health market, potentially generating USD 3-9 billion annually within three years.

Key Takeaways

  • NUTRESTORE is targeting a USD 7.2 billion global bone health supplement market, growing at 6.1% annually.
  • Differentiation hinges on clinical evidence, delivery system, and consumer accessibility.
  • Revenue projections indicate USD 2.5 billion in 2026, rising to USD 9 billion by 2028.
  • Regulatory and market entry risks require mitigation through robust clinical data and strategic partnerships.
  • Long-term success depends on establishing a credible, clinically validated brand in a competitive landscape.

FAQs

1. When is NUTRESTORE expected to launch commercially?
Projected approval and market entry are anticipated around 2025, contingent on clinical trial results and regulatory review.

2. How does NUTRESTORE differentiate from existing osteoporosis drugs?
It is positioned as a non-prescription supplement with a targeted delivery system, emphasizing safety, convenience, and potential fewer side effects compared to bisphosphonates and hormone therapies.

3. What clinical data is needed for NUTRESTORE’s market approval?
Large-scale, randomized controlled trials demonstrating efficacy in improving bone density and reducing fracture risk are essential.

4. What distribution channels will be critical for NUTRESTORE’s success?
Pharmacies, hospitals, online health platforms, and direct-to-consumer models will be central for market penetration.

5. What licensing or partnership opportunities exist?
Strategic collaborations with pharmaceutical companies and distributors can enhance regulatory navigation, manufacturing, and marketing capabilities.


References

[1] MarketsandMarkets. (2022). Bone Health Supplements Market Size, Share & Trends Analysis.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.